Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Selinexor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Karyopharm presents Selinexor in Myelofibrosis at 2025 EHA Meeting
    Karyopharm presents Selinexor in Myelofibrosis at 2025 EHA Meeting

    14 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-announces-poster-presentation-on-selinexor-in-myelofibrosis-at-the-2025-european-hematology-association-annual-meeting-302454678.html

    PR NEWSWIRE
    14 May 2025
    Share Share
    Karyopharm Reports Q1 2025 Results and New Data in Myelofibrosis
    Karyopharm Reports Q1 2025 Results and New Data in Myelofibrosis

    12 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-first-quarter-2025-financial-results-and-announces-new-data-in-myelofibrosis-that-further-suggests-selinexor-may-lead-to-meaningful-spleen-volume-reduction-symptom-improvement-hemoglobin-stabilization-and-dise-302452744.html

    PR NEWSWIRE
    12 May 2025
    Share Share
    Xpovio Approved for Commercialization in Indonesia,
    Xpovio Approved for Commercialization in Indonesia,

    04 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xpovio-selinexor-approved-for-commercialization-in-indonesia-further-expanding-antengenes-commercial-presence-in-apac-302392606.html

    PR NEWSWIRE
    04 Mar 2025
    Share Share
    Antengene’s XPOVIO Gains Public Health Insurance Coverage In Taiwan
    Antengene’s XPOVIO Gains Public Health Insurance Coverage In Taiwan

    13 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-announces-xpovio-approved-for-public-health-insurance-coverage-in-taiwan-market-benefiting-more-patients-with-rr-mm-in-the-region-302375795.html

    PR NEWSWIRE
    13 Feb 2025
    Share Share
    Antengene Presents Late-Stage Selinexor Results at ASH 2024
    Antengene Presents Late-Stage Selinexor Results at ASH 2024

    09 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-presents-results-from-two-late-stage-clinical-studies-of-selinexor-at-ash-2024-302324771.html

    PR NEWSWIRE
    09 Dec 2024
    Share Share
    Karyopharm to Present Selinexor Data at ASH Annual Meeting
    Karyopharm to Present Selinexor Data at ASH Annual Meeting

    18 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-to-present-selinexor-data-at-the-66th-american-society-of-hematology-annual-meeting-and-exposition-302307992.html

    PR NEWSWIRE
    18 Nov 2024
    Share Share